BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, April 29, 2024
See today's BioWorld
Home
» PTC, CV In Potential $345M Cardiovascular Agreement
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
PTC, CV In Potential $345M Cardiovascular Agreement
June 13, 2006
By
Karen Carey
No Comments
Less than three months after signing its first major preclinical deal focused on infectious disease, PTC Therapeutics Inc. topped it with a new cardiovascular collaboration worth up to $345 million with CV Therapeutics Inc. (BioWorld Today)
BioWorld